Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Agilent Technologies, Inc. (A)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
153.27+0.68 (+0.45%)
At close: 4:02PM EDT
153.31 +0.04 (+0.03%)
After hours: 07:42PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close152.59
Open153.14
Bid153.31 x 1000
Ask153.03 x 800
Day's Range152.55 - 153.89
52 Week Range100.65 - 179.57
Volume1,361,236
Avg. Volume1,614,317
Market Cap46.701B
Beta (5Y Monthly)0.99
PE Ratio (TTM)59.02
EPS (TTM)2.60
Earnings DateNov 22, 2021 - Nov 26, 2021
Forward Dividend & Yield0.78 (0.45%)
Ex-Dividend DateJul 02, 2021
1y Target Est173.35
  • Business Wire

    Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

    SANTA CLARA, Calif., October 13, 2021--Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered. This is the first IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio and was de

  • Insider Monkey

    Should I Avoid Agilent Technologies Inc. (A)?

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

Advertisement
Advertisement